Literature DB >> 12124991

Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemia.

Pin Yue1, Bo Yuan, Daniela S Gerhard, Rosalind J Neuman, William L Isley, William S Harris, Gustav Schonfeld.   

Abstract

Familial hypobetalipoproteinemia (FHBL) is a genetic disorder characterized by low levels of apoB-100 and LDL cholesterol. Truncation-producing mutations of apoB (chromosome 2) are among several potential causes of FHBL in patients. Ten new families with FHBL linked to chromosome 2 were identified. In Family 8, a 4432delT in exon 26 produces a frame-shift and a premature stop codon predicted to produce a truncated apoB-30.9. Even though this truncation is just 10 amino acid shorter than the well-documented apoB-31, which is readily detectable in plasma, apoB-30.9 is undetectable. Most truncations shorter than apoB-30 are not detectable in plasma. In Family 34, an acceptor splicing mutation at position -1 of exon 14 changes the acceptor splice site AG to AA. Two families (Family 50 and 52) had mutations (apoB-9 and apoB-29) reported previously. In Family 98, a novel point mutation in exon 26 (11163T>G) causes a premature stop codon, and produces a truncated apoB-80.5 readily detectable in plasma. Sequencing of the ApoB gene in families 1, 5, 18, 58, and 59 did not reveal mutations. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124991     DOI: 10.1002/humu.10101

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

Review 1.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

2.  Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia.

Authors:  Enza Di Leo; Lucia Magnolo; Sandra Lancellotti; Lory Crocè; Luca Visintin; Claudio Tiribelli; Stefano Bertolini; Sebastiano Calandra; Patrizia Tarugi
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

3.  APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants.

Authors:  Xavier Vanhoye; Alexandre Janin; Amandine Caillaud; Antoine Rimbert; Fabienne Venet; Morgane Gossez; Wieneke Dijk; Oriane Marmontel; Séverine Nony; Charlotte Chatelain; Christine Durand; Pierre Lindenbaum; Jennifer Rieusset; Bertrand Cariou; Philippe Moulin; Mathilde Di Filippo
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

4.  Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis.

Authors:  Mindy C W Lam; Janakie Singham; Robert A Hegele; Maziar Riazy; Matti A Hiob; Gordon Francis; Urs P Steinbrecher
Journal:  Case Rep Gastroenterol       Date:  2012-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.